Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer
Background: We aimed to investigate the prognostic value of tumour-infiltrating lymphocytes’ (TILs) expression in pretreatment specimens from patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT). Methods: The prevalence of CD3+, CD8+, CD4+ and F...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2014-01, Vol.110 (2), p.501-509 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 509 |
|---|---|
| container_issue | 2 |
| container_start_page | 501 |
| container_title | British journal of cancer |
| container_volume | 110 |
| creator | Balermpas, P Michel, Y Wagenblast, J Seitz, O Weiss, C Rödel, F Rödel, C Fokas, E |
| description | Background:
We aimed to investigate the prognostic value of tumour-infiltrating lymphocytes’ (TILs) expression in pretreatment specimens from patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT).
Methods:
The prevalence of CD3+, CD8+, CD4+ and FOXP3+ TILs was assessed using immunohistochemistry in tumour tissue obtained from 101 patients before CRT and was correlated with clinicopathological characteristics as well as local failure-free- (LFFS), distant metastases free- (DMFS), progression-free (PFS) and overall survival (OS). Survival curves were measured using the Kaplan–Meier method, and differences in survival between the groups were estimated using the log-rank test. Prognostic effects of TIL subset density were determined using the Cox regression analysis.
Results:
With a mean follow-up of 25 months (range, 2.3–63 months), OS at 2 years was 57.4% for the entire cohort. Patients with high immunohistochemical CD3 and CD8 expression had significantly increased OS (
P
=0.024 and
P
=0.028), PFS (
P
=0.044 and
P
=0.047) and DMFS (
P
=0.021 and
P
=0.026) but not LFFS (
P
=0.90 and
P
=0.104) in multivariate analysis that included predictive clinicopathologic factors, such as age, sex, T-stage, N-stage, tumour grading and localisation. Neither CD4 nor FOXP3 expression showed significance for the clinical outcome. The lower N-stage was associated with improved OS in the multivariate analysis (
P
=0.049).
Conclusion:
The positive correlation between a high number of infiltrating CD3+ and CD8+ cells and clinical outcome indicates that TILs may have a beneficial role in HNSCC patients and may serve as a biomarker to identify patients likely to benefit from definitive CRT. |
| doi_str_mv | 10.1038/bjc.2013.640 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3899751</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3187299871</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-dad827eb1bc33c492197ccac9876517e87bd38b3b5328924de5cda9b21b839103</originalsourceid><addsrcrecordid>eNptkc-L1DAUx4Mo7uzozbMERNiDHfOjnSSXBVn8BQte1nNIk9dpxjapSbsw_70ZZlxX8RTC-_De9wdCryjZUMLl-3ZvN4xQvtnW5Ala0YazikomnqIVIURURDFygS5z3pevIlI8Rxespkyxulmh_m4Z45IqHzo_zMnMPuzwcBinPtrDDBlPCZy3M06Qpxgy4DliB50Pfvb3gG0PY0zG-Tj3kMx0wD7gHozDJjgcwP7A1gQL6QV61pkhw8vzu0bfP328u_lS3X77_PXmw21lG8rnyhlXtENLW8u5rRWjSlhrrJJi21ABUrSOy5a3xaYsFhw01hnVMtpKrkoga3R92jst7QjOQiiuBj0lP5p00NF4_fck-F7v4r3mUilRNKzR1XlBij8XyLMefbYwDCZAXLKmDSm3laCqoG_-Qfcly1DsaVorojgn26OidyfKpphzgu5BDCX6WKEuFepjhbpUWPDXjw08wL87K8DbM2CyNUOXSr4-_-Ek44qII1eduFxGYQfpkbr_Hf4FhSa1TQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490933060</pqid></control><display><type>article</type><title>Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer</title><source>MEDLINE</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Balermpas, P ; Michel, Y ; Wagenblast, J ; Seitz, O ; Weiss, C ; Rödel, F ; Rödel, C ; Fokas, E</creator><creatorcontrib>Balermpas, P ; Michel, Y ; Wagenblast, J ; Seitz, O ; Weiss, C ; Rödel, F ; Rödel, C ; Fokas, E</creatorcontrib><description>Background:
We aimed to investigate the prognostic value of tumour-infiltrating lymphocytes’ (TILs) expression in pretreatment specimens from patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT).
Methods:
The prevalence of CD3+, CD8+, CD4+ and FOXP3+ TILs was assessed using immunohistochemistry in tumour tissue obtained from 101 patients before CRT and was correlated with clinicopathological characteristics as well as local failure-free- (LFFS), distant metastases free- (DMFS), progression-free (PFS) and overall survival (OS). Survival curves were measured using the Kaplan–Meier method, and differences in survival between the groups were estimated using the log-rank test. Prognostic effects of TIL subset density were determined using the Cox regression analysis.
Results:
With a mean follow-up of 25 months (range, 2.3–63 months), OS at 2 years was 57.4% for the entire cohort. Patients with high immunohistochemical CD3 and CD8 expression had significantly increased OS (
P
=0.024 and
P
=0.028), PFS (
P
=0.044 and
P
=0.047) and DMFS (
P
=0.021 and
P
=0.026) but not LFFS (
P
=0.90 and
P
=0.104) in multivariate analysis that included predictive clinicopathologic factors, such as age, sex, T-stage, N-stage, tumour grading and localisation. Neither CD4 nor FOXP3 expression showed significance for the clinical outcome. The lower N-stage was associated with improved OS in the multivariate analysis (
P
=0.049).
Conclusion:
The positive correlation between a high number of infiltrating CD3+ and CD8+ cells and clinical outcome indicates that TILs may have a beneficial role in HNSCC patients and may serve as a biomarker to identify patients likely to benefit from definitive CRT.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2013.640</identifier><identifier>PMID: 24129245</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/67/1059/485 ; 692/699/67/1059/99 ; 692/699/67/1536 ; 692/700/1750 ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Biopsy ; Cancer Research ; Cancer therapies ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - radiotherapy ; Carcinoma, Squamous Cell - therapy ; Chemoradiotherapy ; Chemotherapy ; Disease Progression ; Drug Resistance ; Epidemiology ; Female ; Head & neck cancer ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - pathology ; Head and Neck Neoplasms - radiotherapy ; Head and Neck Neoplasms - therapy ; Human papillomavirus ; Humans ; Immune system ; Immunohistochemistry ; Lymphocytes ; Lymphocytes, Tumor-Infiltrating - immunology ; Lymphocytes, Tumor-Infiltrating - pathology ; Male ; Medical prognosis ; Medical sciences ; Metastasis ; Middle Aged ; Molecular Diagnostics ; Molecular Medicine ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Multivariate analysis ; Oncology ; Otorhinolaryngology (head neck, general aspects and miscellaneous) ; Otorhinolaryngology. Stomatology ; Prognosis ; Radiation therapy ; Squamous Cell Carcinoma of Head and Neck ; Tumors</subject><ispartof>British journal of cancer, 2014-01, Vol.110 (2), p.501-509</ispartof><rights>The Author(s) 2014</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jan 21, 2014</rights><rights>Copyright © 2014 Cancer Research UK 2014 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-dad827eb1bc33c492197ccac9876517e87bd38b3b5328924de5cda9b21b839103</citedby><cites>FETCH-LOGICAL-c513t-dad827eb1bc33c492197ccac9876517e87bd38b3b5328924de5cda9b21b839103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899751/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899751/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28239075$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24129245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Balermpas, P</creatorcontrib><creatorcontrib>Michel, Y</creatorcontrib><creatorcontrib>Wagenblast, J</creatorcontrib><creatorcontrib>Seitz, O</creatorcontrib><creatorcontrib>Weiss, C</creatorcontrib><creatorcontrib>Rödel, F</creatorcontrib><creatorcontrib>Rödel, C</creatorcontrib><creatorcontrib>Fokas, E</creatorcontrib><title>Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
We aimed to investigate the prognostic value of tumour-infiltrating lymphocytes’ (TILs) expression in pretreatment specimens from patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT).
Methods:
The prevalence of CD3+, CD8+, CD4+ and FOXP3+ TILs was assessed using immunohistochemistry in tumour tissue obtained from 101 patients before CRT and was correlated with clinicopathological characteristics as well as local failure-free- (LFFS), distant metastases free- (DMFS), progression-free (PFS) and overall survival (OS). Survival curves were measured using the Kaplan–Meier method, and differences in survival between the groups were estimated using the log-rank test. Prognostic effects of TIL subset density were determined using the Cox regression analysis.
Results:
With a mean follow-up of 25 months (range, 2.3–63 months), OS at 2 years was 57.4% for the entire cohort. Patients with high immunohistochemical CD3 and CD8 expression had significantly increased OS (
P
=0.024 and
P
=0.028), PFS (
P
=0.044 and
P
=0.047) and DMFS (
P
=0.021 and
P
=0.026) but not LFFS (
P
=0.90 and
P
=0.104) in multivariate analysis that included predictive clinicopathologic factors, such as age, sex, T-stage, N-stage, tumour grading and localisation. Neither CD4 nor FOXP3 expression showed significance for the clinical outcome. The lower N-stage was associated with improved OS in the multivariate analysis (
P
=0.049).
Conclusion:
The positive correlation between a high number of infiltrating CD3+ and CD8+ cells and clinical outcome indicates that TILs may have a beneficial role in HNSCC patients and may serve as a biomarker to identify patients likely to benefit from definitive CRT.</description><subject>692/699/67/1059/485</subject><subject>692/699/67/1059/99</subject><subject>692/699/67/1536</subject><subject>692/700/1750</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biopsy</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Disease Progression</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Head & neck cancer</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Head and Neck Neoplasms - therapy</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunohistochemistry</subject><subject>Lymphocytes</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Lymphocytes, Tumor-Infiltrating - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Molecular Diagnostics</subject><subject>Molecular Medicine</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Otorhinolaryngology (head neck, general aspects and miscellaneous)</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Squamous Cell Carcinoma of Head and Neck</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkc-L1DAUx4Mo7uzozbMERNiDHfOjnSSXBVn8BQte1nNIk9dpxjapSbsw_70ZZlxX8RTC-_De9wdCryjZUMLl-3ZvN4xQvtnW5Ala0YazikomnqIVIURURDFygS5z3pevIlI8Rxespkyxulmh_m4Z45IqHzo_zMnMPuzwcBinPtrDDBlPCZy3M06Qpxgy4DliB50Pfvb3gG0PY0zG-Tj3kMx0wD7gHozDJjgcwP7A1gQL6QV61pkhw8vzu0bfP328u_lS3X77_PXmw21lG8rnyhlXtENLW8u5rRWjSlhrrJJi21ABUrSOy5a3xaYsFhw01hnVMtpKrkoga3R92jst7QjOQiiuBj0lP5p00NF4_fck-F7v4r3mUilRNKzR1XlBij8XyLMefbYwDCZAXLKmDSm3laCqoG_-Qfcly1DsaVorojgn26OidyfKpphzgu5BDCX6WKEuFepjhbpUWPDXjw08wL87K8DbM2CyNUOXSr4-_-Ek44qII1eduFxGYQfpkbr_Hf4FhSa1TQ</recordid><startdate>20140121</startdate><enddate>20140121</enddate><creator>Balermpas, P</creator><creator>Michel, Y</creator><creator>Wagenblast, J</creator><creator>Seitz, O</creator><creator>Weiss, C</creator><creator>Rödel, F</creator><creator>Rödel, C</creator><creator>Fokas, E</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7T5</scope><scope>5PM</scope></search><sort><creationdate>20140121</creationdate><title>Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer</title><author>Balermpas, P ; Michel, Y ; Wagenblast, J ; Seitz, O ; Weiss, C ; Rödel, F ; Rödel, C ; Fokas, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-dad827eb1bc33c492197ccac9876517e87bd38b3b5328924de5cda9b21b839103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>692/699/67/1059/485</topic><topic>692/699/67/1059/99</topic><topic>692/699/67/1536</topic><topic>692/700/1750</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biopsy</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Disease Progression</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Head & neck cancer</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Head and Neck Neoplasms - therapy</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunohistochemistry</topic><topic>Lymphocytes</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Lymphocytes, Tumor-Infiltrating - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Molecular Diagnostics</topic><topic>Molecular Medicine</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Otorhinolaryngology (head neck, general aspects and miscellaneous)</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Squamous Cell Carcinoma of Head and Neck</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Balermpas, P</creatorcontrib><creatorcontrib>Michel, Y</creatorcontrib><creatorcontrib>Wagenblast, J</creatorcontrib><creatorcontrib>Seitz, O</creatorcontrib><creatorcontrib>Weiss, C</creatorcontrib><creatorcontrib>Rödel, F</creatorcontrib><creatorcontrib>Rödel, C</creatorcontrib><creatorcontrib>Fokas, E</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Immunology Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Balermpas, P</au><au>Michel, Y</au><au>Wagenblast, J</au><au>Seitz, O</au><au>Weiss, C</au><au>Rödel, F</au><au>Rödel, C</au><au>Fokas, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2014-01-21</date><risdate>2014</risdate><volume>110</volume><issue>2</issue><spage>501</spage><epage>509</epage><pages>501-509</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
We aimed to investigate the prognostic value of tumour-infiltrating lymphocytes’ (TILs) expression in pretreatment specimens from patients with head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiotherapy (CRT).
Methods:
The prevalence of CD3+, CD8+, CD4+ and FOXP3+ TILs was assessed using immunohistochemistry in tumour tissue obtained from 101 patients before CRT and was correlated with clinicopathological characteristics as well as local failure-free- (LFFS), distant metastases free- (DMFS), progression-free (PFS) and overall survival (OS). Survival curves were measured using the Kaplan–Meier method, and differences in survival between the groups were estimated using the log-rank test. Prognostic effects of TIL subset density were determined using the Cox regression analysis.
Results:
With a mean follow-up of 25 months (range, 2.3–63 months), OS at 2 years was 57.4% for the entire cohort. Patients with high immunohistochemical CD3 and CD8 expression had significantly increased OS (
P
=0.024 and
P
=0.028), PFS (
P
=0.044 and
P
=0.047) and DMFS (
P
=0.021 and
P
=0.026) but not LFFS (
P
=0.90 and
P
=0.104) in multivariate analysis that included predictive clinicopathologic factors, such as age, sex, T-stage, N-stage, tumour grading and localisation. Neither CD4 nor FOXP3 expression showed significance for the clinical outcome. The lower N-stage was associated with improved OS in the multivariate analysis (
P
=0.049).
Conclusion:
The positive correlation between a high number of infiltrating CD3+ and CD8+ cells and clinical outcome indicates that TILs may have a beneficial role in HNSCC patients and may serve as a biomarker to identify patients likely to benefit from definitive CRT.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>24129245</pmid><doi>10.1038/bjc.2013.640</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2014-01, Vol.110 (2), p.501-509 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3899751 |
| source | MEDLINE; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | 692/699/67/1059/485 692/699/67/1059/99 692/699/67/1536 692/700/1750 Biological and medical sciences Biomedical and Life Sciences Biomedicine Biopsy Cancer Research Cancer therapies Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy Carcinoma, Squamous Cell - therapy Chemoradiotherapy Chemotherapy Disease Progression Drug Resistance Epidemiology Female Head & neck cancer Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - pathology Head and Neck Neoplasms - radiotherapy Head and Neck Neoplasms - therapy Human papillomavirus Humans Immune system Immunohistochemistry Lymphocytes Lymphocytes, Tumor-Infiltrating - immunology Lymphocytes, Tumor-Infiltrating - pathology Male Medical prognosis Medical sciences Metastasis Middle Aged Molecular Diagnostics Molecular Medicine Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Multivariate analysis Oncology Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology Prognosis Radiation therapy Squamous Cell Carcinoma of Head and Neck Tumors |
| title | Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T10%3A05%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumour-infiltrating%20lymphocytes%20predict%20response%20to%20definitive%20chemoradiotherapy%20in%20head%20and%20neck%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Balermpas,%20P&rft.date=2014-01-21&rft.volume=110&rft.issue=2&rft.spage=501&rft.epage=509&rft.pages=501-509&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2013.640&rft_dat=%3Cproquest_pubme%3E3187299871%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490933060&rft_id=info:pmid/24129245&rfr_iscdi=true |